Connect Biopharma (NASDAQ:CNTB) Earns Buy Rating from HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

A number of other analysts also recently weighed in on CNTB. Canaccord Genuity Group cut their price target on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, September 16th. Piper Sandler began coverage on shares of Connect Biopharma in a research report on Friday, June 26th. They issued an “overweight” rating and a $7.00 price target on the stock. BTIG Research cut their price target on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Wall Street Zen upgraded shares of Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Oppenheimer cut their price target on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.14.

Connect Biopharma Trading Down 3.6%

Shares of NASDAQ CNTB traded down $0.03 during mid-day trading on Thursday, hitting $0.91. The company’s stock had a trading volume of 752,425 shares, compared to its average volume of 1,438,313. The stock has a market cap of $57.37 million, a price-to-earnings ratio of -0.77 and a beta of -0.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. Connect Biopharma has a one year low of $0.85 and a one year high of $3.82. The company’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.23.

Connect Biopharma (NASDAQ:CNTB) last issued its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. The business had revenue of $2.75 million during the quarter, compared to the consensus estimate of $0.74 million. On average, sell-side analysts anticipate that Connect Biopharma will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Connect Biopharma

Hedge funds have recently bought and sold shares of the stock. ADAR1 Capital Management LLC acquired a new stake in Connect Biopharma during the 1st quarter worth approximately $1,945,000. Bank of America Corp DE acquired a new stake in shares of Connect Biopharma in the first quarter valued at approximately $41,000. Knott David M Jr raised its holdings in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after purchasing an additional 187,835 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Connect Biopharma in the first quarter valued at approximately $135,000. Finally, Richmond Brothers Inc. acquired a new stake in shares of Connect Biopharma in the fourth quarter valued at approximately $489,000. 58.72% of the stock is currently owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.